ArticleHypertension (Dallas, Tex. : 1979)2017
2-Methoxyestradiol Reduces Angiotensin II-Induced Hypertension and Renal Dysfunction in Ovariectomized Female and Intact Male Mice.
Open access · bronzeAbstract readComparative Study
In one paragraph
Article in Hypertension (Dallas, Tex. : 1979), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
3.1field-weighted citation impact, top 9% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 30 citations in OpenAlex.
- Central Interaction of 2-Methoxyestradiol and Lipoxygenase in AngII-Hypertension.Hypertension (Dallas, Tex. : 1979) · 2025Article
- Hypertension Management in Women With a Multidisciplinary Approach.Mayo Clinic proceedings · 2025Review
- Ovariectomy Via 12/15-lipoxygenase Augments Angiotensin II-Induced Hypertension and Its Pathogenesis in Female Mice.Hypertension (Dallas, Tex. : 1979) · 2023Article
- G Protein-Coupled Estrogen Receptor GPER: Molecular Pharmacology and Therapeutic Applications.Annual review of pharmacology and toxicology · 2023Review
- Role of sex hormones in diabetic nephropathy.Frontiers in endocrinology · 2023Review
- 2-Methoxyestradiol TPGS Micelles Attenuate Cyclosporine A-Induced Nephrotoxicity in Rats through Inhibition of TGF-β1 and p-ERK1/2 Axis.Antioxidants (Basel, Switzerland) · 2022Article
- Immunosuppression by Mycophenolate Mofetil Mitigates Intrarenal Angiotensinogen Augmentation in Angiotensin II-Dependent Hypertension.International journal of molecular sciences · 2022Article
- Estrogen Metabolite 2-Methoxyestradiol Attenuates Blood Pressure in Hypertensive Rats by Downregulating Angiotensin Type 1 Receptor.Frontiers in physiology · 2022Article
- 2-Methoxyestradiol Ameliorates Angiotensin II-Induced Hypertension by Inhibiting Cytosolic Phospholipase AHypertension (Dallas, Tex. : 1979) · 2021Article
- CYP1B1 as a therapeutic target in cardio-oncology.Clinical science (London, England : 1979) · 2020Article
- Cytochrome P4501B1 in bone marrow is co-expressed with key markers of mesenchymal stem cells. BMS2 cell line models PAH disruption of bone marrow niche development functions.Toxicology and applied pharmacology · 2020Article
- Nuclear Activation Function 2 Estrogen Receptor α Attenuates Arterial and Renal Alterations Due to Aging and Hypertension in Female Mice.Journal of the American Heart Association · 2020Article
- 6β-Hydroxytestosterone, a metabolite of testosterone generated by CYP1B1, contributes to vascular changes in angiotensin II-induced hypertension in male mice.Biology of sex differences · 2020Article
- Article
- Estradiol Metabolism: Crossroads in Pulmonary Arterial Hypertension.International journal of molecular sciences · 2019Review
- 2-Methoxyestradiol Attenuates Angiotensin II-Induced Hypertension, Cardiovascular Remodeling, and Renal Injury.Journal of cardiovascular pharmacology · 2019Article
- Advances in Cardiovascular Disease Lipid Research Can Provide Novel Insights Into Mycobacterial Pathogenesis.Frontiers in cellular and infection microbiology · 2019Review
- GPCRs in context: sexual dimorphism in the cardiovascular system.British journal of pharmacology · 2018Review
Corrections and comments
- Commented on by
Authors and funding
9 authors at 3 institutions in 1 country.
Ajeeth K PingiliFrom the Department of Pharmacology, College of Medicine, University of Tennessee Health Science Center, Memphis (A.K.P., K.N.D., S.T., N.S.K., K.U.M.); Department of Physiology, Hypertension & Renal Center, School of Medicine, Tulane University, New Orleans, LA (A.K., D.S.A.M., L.G.N.); and Laboratory of Metabolism, National Cancer Institute, Bethesda, MD (F.J.G.).
Karen N DavidgeFrom the Department of Pharmacology, College of Medicine, University of Tennessee Health Science Center, Memphis (A.K.P., K.N.D., S.T., N.S.K., K.U.M.); Department of Physiology, Hypertension & Renal Center, School of Medicine, Tulane University, New Orleans, LA (A.K., D.S.A.M., L.G.N.); and Laboratory of Metabolism, National Cancer Institute, Bethesda, MD (F.J.G.).
Shyamala ThirunavukkarasuFrom the Department of Pharmacology, College of Medicine, University of Tennessee Health Science Center, Memphis (A.K.P., K.N.D., S.T., N.S.K., K.U.M.); Department of Physiology, Hypertension & Renal Center, School of Medicine, Tulane University, New Orleans, LA (A.K., D.S.A.M., L.G.N.); and Laboratory of Metabolism, National Cancer Institute, Bethesda, MD (F.J.G.).
Nayaab S KhanFrom the Department of Pharmacology, College of Medicine, University of Tennessee Health Science Center, Memphis (A.K.P., K.N.D., S.T., N.S.K., K.U.M.); Department of Physiology, Hypertension & Renal Center, School of Medicine, Tulane University, New Orleans, LA (A.K., D.S.A.M., L.G.N.); and Laboratory of Metabolism, National Cancer Institute, Bethesda, MD (F.J.G.).
Akemi KatsuradaFrom the Department of Pharmacology, College of Medicine, University of Tennessee Health Science Center, Memphis (A.K.P., K.N.D., S.T., N.S.K., K.U.M.); Department of Physiology, Hypertension & Renal Center, School of Medicine, Tulane University, New Orleans, LA (A.K., D.S.A.M., L.G.N.); and Laboratory of Metabolism, National Cancer Institute, Bethesda, MD (F.J.G.).
Dewan S A MajidFrom the Department of Pharmacology, College of Medicine, University of Tennessee Health Science Center, Memphis (A.K.P., K.N.D., S.T., N.S.K., K.U.M.); Department of Physiology, Hypertension & Renal Center, School of Medicine, Tulane University, New Orleans, LA (A.K., D.S.A.M., L.G.N.); and Laboratory of Metabolism, National Cancer Institute, Bethesda, MD (F.J.G.).
Frank J GonzalezFrom the Department of Pharmacology, College of Medicine, University of Tennessee Health Science Center, Memphis (A.K.P., K.N.D., S.T., N.S.K., K.U.M.); Department of Physiology, Hypertension & Renal Center, School of Medicine, Tulane University, New Orleans, LA (A.K., D.S.A.M., L.G.N.); and Laboratory of Metabolism, National Cancer Institute, Bethesda, MD (F.J.G.).
L Gabriel NavarFrom the Department of Pharmacology, College of Medicine, University of Tennessee Health Science Center, Memphis (A.K.P., K.N.D., S.T., N.S.K., K.U.M.); Department of Physiology, Hypertension & Renal Center, School of Medicine, Tulane University, New Orleans, LA (A.K., D.S.A.M., L.G.N.); and Laboratory of Metabolism, National Cancer Institute, Bethesda, MD (F.J.G.).
Kafait U MalikFrom the Department of Pharmacology, College of Medicine, University of Tennessee Health Science Center, Memphis (A.K.P., K.N.D., S.T., N.S.K., K.U.M.); Department of Physiology, Hypertension & Renal Center, School of Medicine, Tulane University, New Orleans, LA (A.K., D.S.A.M., L.G.N.); and Laboratory of Metabolism, National Cancer Institute, Bethesda, MD (F.J.G.). kmalik@uthsc.edu.
National Cancer Institute · USTulane University · USUniversity of Tennessee Health Science Center · US
Funding
Xenobiotic ReceptorsZIABC005708 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI GONZALEZ, FRANK J · 2009 to 2025
$16.4MAngiotensins, Prostaglandins and Adrenergic InteractionsR01HL019134 · NHLBI · UNIVERSITY OF TENNESSEE HEALTH SCI CTR · PI KAFAIT U MALIK · 1985 to 2026
$14.7MTranslational Research in Hypertension and Renal BiologyP30GM103337 · NIGMS · TULANE UNIVERSITY OF LOUISIANA · PI NAVAR, LUIS GABRIEL · 2012 to 2016
$5.8MRenal Function Derangements in HypertensionR01HL026371 · NHLBI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI NAVAR, LUIS GABRIEL · 1985 to 2010
$3.4MEicosanoid-Induced Vascular Growth During InjuryR01HL079109 · NHLBI · UNIVERSITY OF TENNESSEE HEALTH SCI CTR · PI MALIK, KAFAIT U · 2005 to 2015
$3.3MSuperoxide and nitric Oxide Interactions in the KidneyR01HL066432 · NHLBI · TULANE UNIVERSITY OF LOUISIANA · PI MAJID, DEWAN SYED ABDUL · 2001 to 2012
$3.0MNHLBI NIH HHS R01 HL019134NHLBI NIH HHS R01 HL026371NHLBI NIH HHS R01 HL066432NHLBI NIH HHS R01 HL079109NIGMS NIH HHS P30 GM103337
Abstract
Cytochrome P450 1B1 protects against angiotensin II (Ang II)-induced hypertension and associated cardiovascular changes in female mice, most likely via production of 2-methoxyestradiol. This study was conducted to determine whether 2-methoxyestradiol ameliorates Ang II-induced hypertension, renal dysfunction, and end-organ damage in intact
Indexed as
2-MethoxyestradiolAngiotensin IIAnimalsBlood PressureBlood Pressure DeterminationCytochrome P-450 CYP1B1Disease Models, AnimalEstradiolFemaleHypertensionKidney DiseasesKidney Function TestsMaleMiceMice, Inbred C57BLMice, Transgenic2-MethoxyestradiolAngiotensin IICyp1b1 protein, mouseCytochrome P-450 CYP1B1EstradiolReactive Oxygen Species2-methoxyestradiolCYP1B1end-organ damagehypertensionurinary angiotensinogen
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.